Acadesine (AICA-riboside) improves postischemic cardiac recovery.

Bolling SF, Groh MA, Mattson AM, Grinage RA, Gallagher KP

The Annals of thoracic surgery1 Jul 1992Cited by 24 (Europe PMC)

PMID1610261DOI10.1016/0003-4975(92)91148-3PepBankPUB-01610261

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In dogs after myocardial ischemia, acadesine did not significantly change heart rate versus standard cardioplegia control after bypass.
In plain wordsIn dogs after heart ischemia, acadesine did not significantly change heart rate compared with standard cardioplegia control after bypass.
Peptide
AICAR (acadesine)
Outcome
No significant changeHeart rate after bypass
Study
dogn = 16
Global myocardial ischemia with cardiopulmonary bypass
Comparator
Standard cardioplegia control
Outcome group
Heart function · Cardiovascular
Studied dose
2.5 mg.kg-1.min-1 for 5 minutes, then 0.5 mg.kg-1.min-1 intravenously; 20 mumol/L in cardioplegia · Intravenous and cardioplegic solution · Before and during ischemia until 10 minutes after aortic cross-clamp removalAs given in this study (dog).
Source sentences
Summary
There were no significant differences in heart rate, left atrial pressure, or systemic vascular resistance between groups after weaning from bypass.
3 context sentences(design, population, supporting numbers)
Summary · context
To test if acadesine (5-aminoimidazole-4-carboxamide riboside), a purine precursor, has cardioprotective effects, 16 dogs were placed on total cardiopulmonary bypass and subjected to global myocardial ischemia.
Summary · context
Hemodynamic recovery was compared between a control (n = 8) group receiving standard cardioplegia and an acadesine (n = 8) group pretreated with intravenous acadesine (2.5 mg.kg-1.min-1 for 5 minutes, then 0.5 mg.kg-1.min-1) before ischemia, during ischemia, and until 10 minutes after removal of the aortic cross-clamp.
Summary · context
Additionally, in the acadesine group the cardioplegia also contained 20 mumol/L acadesine.
Report a problemFND-0161026101
02AnimalAnimal study (in vivo)Efficacy outcome
In dogs after myocardial ischemia, acadesine did not significantly change left atrial pressure versus standard cardioplegia control after bypass.
In plain wordsIn dogs after heart ischemia, acadesine did not significantly change left atrial pressure compared with standard cardioplegia control after bypass.
Peptide
AICAR (acadesine)
Outcome
No significant changeLeft atrial pressure after bypass
Study
dogn = 16
Global myocardial ischemia with cardiopulmonary bypass
Comparator
Standard cardioplegia control
Outcome group
Heart function · Cardiovascular
Studied dose
2.5 mg.kg-1.min-1 for 5 minutes, then 0.5 mg.kg-1.min-1 intravenously; 20 mumol/L in cardioplegia · Intravenous and cardioplegic solution · Before and during ischemia until 10 minutes after aortic cross-clamp removalAs given in this study (dog).
Source sentences
Summary
There were no significant differences in heart rate, left atrial pressure, or systemic vascular resistance between groups after weaning from bypass.
3 context sentences(design, population, supporting numbers)
Summary · context
To test if acadesine (5-aminoimidazole-4-carboxamide riboside), a purine precursor, has cardioprotective effects, 16 dogs were placed on total cardiopulmonary bypass and subjected to global myocardial ischemia.
Summary · context
Hemodynamic recovery was compared between a control (n = 8) group receiving standard cardioplegia and an acadesine (n = 8) group pretreated with intravenous acadesine (2.5 mg.kg-1.min-1 for 5 minutes, then 0.5 mg.kg-1.min-1) before ischemia, during ischemia, and until 10 minutes after removal of the aortic cross-clamp.
Summary · context
Additionally, in the acadesine group the cardioplegia also contained 20 mumol/L acadesine.
Report a problemFND-0161026102
03AnimalAnimal study (in vivo)Efficacy outcome
In dogs after myocardial ischemia, acadesine did not significantly change systemic vascular resistance versus standard cardioplegia control after bypass.
In plain wordsIn dogs after heart ischemia, acadesine did not significantly change systemic vascular resistance compared with standard cardioplegia control after bypass.
Peptide
AICAR (acadesine)
Outcome
No significant changeSystemic vascular resistance after bypass
Study
dogn = 16
Global myocardial ischemia with cardiopulmonary bypass
Comparator
Standard cardioplegia control
Outcome group
Heart function · Cardiovascular
Studied dose
2.5 mg.kg-1.min-1 for 5 minutes, then 0.5 mg.kg-1.min-1 intravenously; 20 mumol/L in cardioplegia · Intravenous and cardioplegic solution · Before and during ischemia until 10 minutes after aortic cross-clamp removalAs given in this study (dog).
Source sentences
Summary
There were no significant differences in heart rate, left atrial pressure, or systemic vascular resistance between groups after weaning from bypass.
3 context sentences(design, population, supporting numbers)
Summary · context
To test if acadesine (5-aminoimidazole-4-carboxamide riboside), a purine precursor, has cardioprotective effects, 16 dogs were placed on total cardiopulmonary bypass and subjected to global myocardial ischemia.
Summary · context
Hemodynamic recovery was compared between a control (n = 8) group receiving standard cardioplegia and an acadesine (n = 8) group pretreated with intravenous acadesine (2.5 mg.kg-1.min-1 for 5 minutes, then 0.5 mg.kg-1.min-1) before ischemia, during ischemia, and until 10 minutes after removal of the aortic cross-clamp.
Summary · context
Additionally, in the acadesine group the cardioplegia also contained 20 mumol/L acadesine.
Report a problemFND-0161026103
04AnimalAnimal study (in vivo)Efficacy outcome
In dogs after myocardial ischemia, acadesine improved peak developed pressure recovery versus standard cardioplegia control.
In plain wordsIn dogs after heart ischemia, acadesine improved recovery of heart pressure compared with standard cardioplegia control.
Peptide
AICAR (acadesine)
Outcome
IncreasePeak developed pressure recovery
Study
dogn = 16
Global myocardial ischemia with cardiopulmonary bypass
Comparator
Standard cardioplegia control
Outcome group
Heart function · Cardiovascular
Studied dose
2.5 mg.kg-1.min-1 for 5 minutes, then 0.5 mg.kg-1.min-1 intravenously; 20 mumol/L in cardioplegia · Intravenous and cardioplegic solution · Before and during ischemia until 10 minutes after aortic cross-clamp removalAs given in this study (dog).
Measurements
Peak developed pressure recovery
79 % of baseline
acadesine
Standard deviation
19 % of baseline
acadesine
Peak developed pressure recovery
56 % of baseline
control
Standard deviation
22 % of baseline
control
Source sentences
Summary
Peak developed pressure recovered to 79% +/- 19% (mean +/- standard deviation) of baseline in the acadesine group compared with 56% +/- 22% in the control group (p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
3 context sentences(design, population, supporting numbers)
Summary · context
To test if acadesine (5-aminoimidazole-4-carboxamide riboside), a purine precursor, has cardioprotective effects, 16 dogs were placed on total cardiopulmonary bypass and subjected to global myocardial ischemia.
Summary · context
Hemodynamic recovery was compared between a control (n = 8) group receiving standard cardioplegia and an acadesine (n = 8) group pretreated with intravenous acadesine (2.5 mg.kg-1.min-1 for 5 minutes, then 0.5 mg.kg-1.min-1) before ischemia, during ischemia, and until 10 minutes after removal of the aortic cross-clamp.
Summary · context
Additionally, in the acadesine group the cardioplegia also contained 20 mumol/L acadesine.
Report a problemFND-0161026104

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.